Products
Platform
Research
Market
Learn
Compare Tata Nifty MidSmall Healthcare Index Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.11 | 1.87 |
NAV | ₹12.66 | ₹39.90 |
Fund Started | 08 Apr 2024 | 25 Jun 2018 |
Fund Size | ₹160.07 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 0.25%, if redeemed within 15 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.11
1.87
NAV
₹12.66
₹39.90
Fund Started
08 Apr 2024
25 Jun 2018
Fund Size
₹160.07 Cr
₹6437.36 Cr
Exit Load
Exit load of 0.25%, if redeemed within 15 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 3.94% | 5.80% |
3 Year | - | 26.90% |
5 Year | - | 19.51% |
1 Year
3.94%
5.80%
3 Year
-
26.90%
5 Year
-
19.51%
Holding Analysis
Equity | 100.08% | 97.10% |
Cash | -0.08% | 2.90% |
Equity
100.08%
97.10%
Cash
-0.08%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Fortis Healthcare Ltd. | 9.94% |
Lupin Ltd. | 8.86% |
Laurus Labs Ltd. | 6.91% |
Aurobindo Pharma Ltd. | 5.94% |
Alkem Laboratories Ltd. | 5.78% |
Glenmark Pharmaceuticals Ltd. | 5.31% |
Mankind Pharma Ltd. | 5.03% |
Biocon Ltd. | 4.17% |
Krishna Institute of Medical Sciences Ltd | 3.31% |
Ipca Laboratories Ltd. | 3.29% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Kapil Menon | Dharmesh Kakkad |
Start Date | 02 Jun 2025 | 23 Feb 2021 |
Name
Kapil Menon
Dharmesh Kakkad
Start Date
02 Jun 2025
23 Feb 2021
About Fund
Description | The scheme seeks to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 08 Apr 2024 | 25 Jun 2018 |
Description
The scheme seeks to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
08 Apr 2024
25 Jun 2018